← Leaderboards
Julia C Carnevale
University Of California, San Francisco
$3,472,933
Attributed
$3,472,933
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,472,933 · 3
By mechanism
DP2$1,476,000 · 1
K08$1,316,335 · 1
R01$680,598 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Nevan J Krogan$73,195,859
- Michael T McManus$36,428,993
- John D Gross$17,630,943
- Lishomwa C Ndhlovu$30,426,942
- Danielle L Swaney$10,953,058
Others in their field
Other Emerging Leaders on “Immunocompetent”
- Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai$13,559,983
- Thomas Dick · Rbhs-New Jersey Medical School$6,248,354
- James Even Voss · Scripps Research Institute, The$6,071,440
- Giedre Krenciute · St. Jude Children'S Research Hospital$4,894,202
- Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr$4,461,361
- Stylianos Bournazos · Rockefeller University$4,382,103
Research focus
ImmunocompetentMouse ModelT Cell TherapyTumorResponsePre-Clinical ModelProgramsSolid NeoplasmT-LymphocyteIn VivoAntigensKnock-OutMalignant NeoplasmsEngineeringCell PhysiologyAffectCellsLibrariesMembrane ProteinsGenome-WideCancer CellImmuneCar T Cell TherapyGenome
Grant awards (7)
Genetic Engineering of Myeloid Cells to Treat Cancer$1,476,000
DP2 · FY2025 · CA · contact PI
Decoding the Cullin-5 complex to engineer therapeutic T cells with durable effector function$680,598
R01 · FY2025 · CA · contact PI
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.$263,267
K08 · FY2024 · CA · contact PI
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.$263,267
K08 · FY2023 · CA · contact PI
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.$263,267
K08 · FY2022 · CA · contact PI
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.$263,267
K08 · FY2021 · CA · contact PI
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.$263,267
K08 · FY2020 · CA · contact PI